SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Richard Stark

(Last)

(First)

(Middle)

14 PLAZA DRIVE

(Street)

LATHAM

12110

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/26/2017

3. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, GM - Oncology

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	647	D
Common Stock	3,436⁽¹⁾	D
Common Stock	4,287⁽²⁾	D
Common Stock	4,718⁽³⁾	D
Common Stock	5,345⁽⁴⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Non-Qualified Stock Option (right to buy)	07/27/2017⁽⁵⁾	07/27/2023	Common Stock	12,102	$16.59	D
Non-Qualified Stock Option (right to buy)	07/22/2016⁽⁶⁾	07/22/2022	Common Stock	14,704	$15.95	D
Non-Qualified Stock Option (right to buy)	07/25/2015⁽⁷⁾	07/25/2021	Common Stock	13,575	$14.07	D
Non-Qualified Stock Option (right to buy)	08/06/2014⁽⁸⁾	08/06/2020	Common Stock	17,409	$11.92	D
Non-Qualified Stock Option (right to buy)	08/17/2013⁽⁹⁾	08/17/2019	Common Stock	10,000	$10.63	D
Performance Right	⁽¹⁰⁾	⁽¹⁰⁾	Common Stock	6,872	⁽¹⁰⁾	D
Performance Right	⁽¹¹⁾	⁽¹¹⁾	Common Stock	5,716	⁽¹¹⁾	D
Performance Right	⁽¹²⁾	⁽¹²⁾	Common Stock	6,291	⁽¹²⁾	D

Explanation of Responses:

1. This grant of 3,436 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents 3,436 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 27, 2017, such that 25% of the restricted stock units will vest on each of July 27, 2017, 2018, 2019 and 2020.

2. This grant of 4,287 shares of Common Stock, represents 4,287 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 22, 2016, such that 25% of the restricted stock units vested on July 22, 2016 and 25% of the restricted stock units will vest on each of July 22, 2017, 2018 and 2019. 3,216 restricted stock units remain unvested.

3. This grant of 4,718 shares of Common Stock, represents 4,718 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 25, 2015, such that 25% of the restricted stock units vested on July 25, 2015 and July 25, 2016 and 25% of the restricted stock units will vest on July 25, 2017 and July 25, 2018. 2,360 restricted stock units remain unvested.

4. This grant of 5,345 shares of Common Stock, represents 5,345 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on August 6, 2014, such that 25% of the restricted stock units vested on August 6, 2014, August 6, 2015 and August 6, 2016 and 25% of the restricted stock units will vest on August 6, 2017. 1,337 restricted stock units remain unvested.

5. These stock options vest in four equal annual installments beginning on July 27, 2017, such that 25% of the options will vest on each of July 27, 2017, 2018, 2019 and 2020.

6. These stock options vest in four equal annual installments beginning on July 22, 2016, such that 25% of the options vested on July 22, 2016 and 25% of the options will vest on each of July 22, 2017, 2018 and 2019.

7. These stock options vest in four equal annual installments beginning on July 25, 2015, such that 25% of the options vested on July 25, 2015 and July 25, 2016 and 25% of the options will vest on July 25, 2017 and July 25, 2018.

8. These stock options vest in four equal annual installments beginning on August 6, 2014, such that 25% of the options vested on August 6, 2014, August 6, 2015 and August 6, 2016 and 25% of the options will vest on August 6, 2017.

9. These stock options vest in four equal annual installments beginning on August 17, 2013, such that 25% of the options vested on each of August 17, 2013, 2014, 2015 and 2016.

10. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period covering the Company's fiscal years 2017, 2018 and 2019. Any shares that do not vest at the end of the performance period will be forfeited.

11. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period covering the Company's fiscal years 2016, 2017 and 2018. Any shares that do not vest at the end of the performance period will be forfeited.

12. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period covering the Company's fiscal years 2015, 2016 and 2017. Any shares that do not vest at the end of the performance period will be forfeited.

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney

	/s/ Stephen A. Trowbridge, Attorney in Fact	06/02/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.